Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
304 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05983783 | Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC | recruiting | Phase 3 | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05967949 | A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide. | recruiting | — | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER |
| 1 |
| Aug 1, 2023 |
| clinicaltrials |
| NCT05956639 | Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC | recruiting | Phase 3 | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT05931263 | A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL | recruiting | Phase 3 | 104 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05931328 | The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients. | recruiting | Phase 2 | 28 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05909293 | Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission | recruiting | N/A | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05896813 | CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma | unknown | N/A | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT05264883 | Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML | unknown | Phase 3 | 170 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT05743959 | ctDNA Detection of MRD in Predicting Postoperative Recurrence in Biliary Tract Cancers:A Multicenter Prospective Trial | unknown | — | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT04356846 | A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma | unknown | Phase 1 | 74 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT05834582 | Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer | unknown | Phase 2 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT05834764 | Pyrotinib in Women With High-risk in Early Stage Breast Cancer | recruiting | Phase 2 | 188 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT05817955 | Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN | recruiting | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05808582 | Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer | unknown | Phase 2 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Apr 14, 2023 | clinicaltrials |
| NCT05800054 | Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer | recruiting | N/A | 210 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05764941 | Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer | unknown | — | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT05784987 | R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | unknown | N/A | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 27, 2023 | clinicaltrials |
| NCT05777369 | R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma | unknown | N/A | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 21, 2023 | clinicaltrials |
| NCT05775419 | Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC | recruiting | N/A | 1,216 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT05774028 | Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma | unknown | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 17, 2023 | clinicaltrials |
| NCT05772377 | Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer | unknown | Phase 2 | 36 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 16, 2023 | clinicaltrials |
| NCT05772728 | Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL) | unknown | N/A | 23 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 16, 2023 | clinicaltrials |
| NCT04302350 | Nitrous Oxide for Identifying the Intersegmental Plane in Segmentectomy: A Randomized Controlled Trial | completed | N/A | 81 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT04477616 | Injection Regimen Trial of PEG-rhG-CSF During Breast Cancer Chemotherapy | completed | Phase 2 | 160 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT05430347 | Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast Cancer | unknown | Phase 2 | 80 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05719324 | Checkpoint Inhibitors in Patients With Solid Tumors: a Retrospective Real-world Study | unknown | — | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 10, 2023 | clinicaltrials |
| NCT05708664 | Precision Breast Conserving Surgery With Guidance. | completed | N/A | 92 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT05594381 | A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma. | unknown | Phase 2 | 90 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Oct 26, 2022 | clinicaltrials |
| NCT05493683 | Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer | unknown | Phase 2 | 29 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 21, 2022 | clinicaltrials |
| NCT05584761 | Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML | recruiting | Phase 1 / Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT05540483 | RC-48 Combined With GLS-010 in HER2-overexpressed Patients With Previously Treated Unresectable Biliary Tract Cancer(RIGHT) | unknown | N/A | 31 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 16, 2022 | clinicaltrials |
| NCT05534113 | Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC | unknown | Phase 2 | 38 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Sep 14, 2022 | clinicaltrials |
| NCT05513131 | Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAML | unknown | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT05510219 | Safety Analysis of Intravenous Rapid Infusion of Obinutuzumab in Patients With B-cell Non-Hodgkin's Lymphoma in China | unknown | Phase 2 | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT04219319 | LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma | terminated | Phase 1 | 4 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT05491694 | To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer(HIFU) | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Aug 8, 2022 | clinicaltrials |
| NCT04683965 | Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer | unknown | Phase 2 | 27 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT02749526 | Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial | terminated | Phase 2 | 70 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT03843853 | Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer | withdrawn | Phase 2 | 0 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT04866862 | Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer | unknown | Phase 2 | 32 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT05469061 | Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC | unknown | Phase 2 | 17 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT03946969 | Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer | unknown | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT05444647 | Gut Microbiome Components Predict Response to Neoadjuvant Therapy in HER2-positive Breast Cancer Patients : A Prospective Study | unknown | — | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05426824 | The Whole-course Management of Pegaspargase in ENKTL | unknown | N/A | 72 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT05355155 | Bevacizumab Biosimilar Plus FOLFOX4 in the Treatment of Recurrent HCC After Liver Transplantation | unknown | Phase 2 | 15 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT05356156 | The Safe Study of Routine Closure of Mesenteric Defects Versus Non-closure After Radical Gastrectomy | not yet recruiting | N/A | 1,968 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT05347641 | Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma | not yet recruiting | Phase 2 | 23 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Apr 26, 2022 | clinicaltrials |
| NCT05343377 | A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma | not yet recruiting | N/A | 72 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT05322733 | Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL | unknown | Phase 2 | 25 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT05334147 | Anlotinib Combined With Chemotherapy for the Treatment of HER2 Negative Advanced Breast Cancer(ALOT-BC1) | unknown | — | 315 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Apr 19, 2022 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials